Mineralocorticoid antagonists may be a novel treatment for alcohol use disorder

Normally used to treat cardiovascular disease, the mineralocorticoid antagonist spironolactone has now shown efficacy in decreasing alcohol intake. The study investigated the effects on alcohol consumption in mice, rats and people and is published in Molecular Psychiatry.

Medical News Today